HSM Helius Medical Technologies Inc

Helius Medical Technologies, Inc. to Release Second Quarter 2023 Financial Results on August 10, 2023

Helius Medical Technologies, Inc. to Release Second Quarter 2023 Financial Results on August 10, 2023

NEWTOWN, Pa., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its second quarter 2023 financial results on Thursday, August 10, 2023, after the market closes.

Dane C. Andreeff, President and Chief Executive Officer, and Jeffrey S. Mathiesen, Chief Financial Officer will host a conference call to discuss the results and provide an expanded business update regarding Helius’ progress and plans surrounding the U.S. commercialization of PoNS® as follows:

Date:Thursday, August 10, 2023
Time:4:30 p.m. Eastern Time
Register* (Audio Only):
Webcast:

The webcast will be archived under the Newsroom section of the Company’s investor relations website.

About Helius Medical Technologies, Inc.

Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using non-implantable platform technologies that amplify the brain’s ability to compensate and promote neuroplasticity, improving the lives of people dealing with neurologic diseases. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS®) device. For more information about the PoNS® or Helius Medical Technologies, visit .

About the PoNS Device and PoNS Therapy

The Portable Neuromodulation Stimulator (PoNS) is an innovative orally-applied, non-implantable medical device, inclusive of a controller and mouthpiece, which delivers mild electrical stimulation to the surface of the tongue and it’s used, primarily at home, with physical rehabilitation exercise, to improve balance and gait. The PoNS device is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis (“MS”) and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.

PoNS is also authorized for sale in Canada for three indications: (i) for use as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury (“mmTBI”) and is to be used in conjunction with physical therapy; and (ii) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy; and (iii) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from stroke, to be used in conjunction with physical therapy. PoNS is also authorized for sale in Australia for short term use by healthcare professionals as an adjunct to a therapeutic exercise program to improve balance and gait. For more information visit .

Investor Relations Contact:

Lisa M. Wilson, In-Site Communications, Inc.

T: 212-452-2793

E:



EN
02/08/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Helius Medical Technologies Inc

 PRESS RELEASE

Preeminent SOL Treasury Vehicle, Solana Company (NASDAQ:HSDT), Adds Co...

Preeminent SOL Treasury Vehicle, Solana Company (NASDAQ:HSDT), Adds Coinbase, BitGo, and Anchorage Digital as Custodians NEWTOWN, Pa., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Solana Company, (NASDAQ:HSDT or “the Company"), formerly Helius Medical Technologies, Inc., today announced it has entered into agreements with Coinbase, BitGo and Anchorage Digital to serve as custodians as it continues amassing SOL, the native asset of the Solana Network, as part of its digital assets treasury strategy. “As HSDT continues to operate as the preeminent SOL-focused treasury, establishing relationships with...

 PRESS RELEASE

Solana Company (NASDAQ:HSDT), Formerly Helius, Continues Amassing SOL,...

Solana Company (NASDAQ:HSDT), Formerly Helius, Continues Amassing SOL, the Native Asset of Solana Blockchain NEWTOWN, Pa., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (the "Company" or "HSDT"), today announced its continued acquisition of Solana (“SOL”) tokens as part of its digital asset treasury strategy. The Company now holds over 2.2 million SOL. The Company also holds in excess of $15 million of cash, which it intends to use to further the digital asset treasury strategy. The Company’s combined Solana holdings (at $232.50 per SOL as of October 6th at 12:00AM E...

 PRESS RELEASE

Preeminent SOL Treasury Company Helius (NASDAQ:HSDT) Announces Corpora...

Preeminent SOL Treasury Company Helius (NASDAQ:HSDT) Announces Corporate Name Change to Solana Company and Letter of Intent with Solana Foundation HSDT Solana Company's Mission is to maximize SOL per share on one of the most commercially viable blockchains for consumer applications while delivering consistent on-chain yield for investors HSDT enters into agreement with the Solana Foundation to establish its collaboration and commit to joint initiatives This signifies HSDT’s commitment to building a long-lasting institution that accelerates the growth of Solana and being a powerful advocat...

 PRESS RELEASE

Helius Announces FDA 510(k) Submission for PoNS® Device Label Expansio...

Helius Announces FDA 510(k) Submission for PoNS® Device Label Expansion in Stroke Seeking an indication for gait and balance deficit in patients with chronic symptoms of stroke under its Breakthrough Device Designation NEWTOWN, Pa., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT), today announced the filing of its U.S. Food and Drug Administration (FDA) 510(k) submission for the PoNS (Portable Neuromodulation Stimulator) device label expansion seeking an indication for gait and balance deficit in patients with chronic stroke symptoms. The submission w...

 PRESS RELEASE

Helius Announces Positive Outcome of the Portable Neuromodulation Stim...

Helius Announces Positive Outcome of the Portable Neuromodulation Stimulator PoNS® Stroke Registrational Program and Upcoming Submission to FDA Under Breakthrough Designation NEWTOWN, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced positive outcome from the PoNS (Portable Neuromodulation Stimulator) Stroke Registrational Program (SRP) supporting a planned FDA submission seeking an indication for gait and balance defi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch